Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Anti-Angiogenesis Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Properties Under Experimental Model Publisher Pubmed



Rastegaripouyani M1, 2 ; Mostafaie A3 ; Mansouri K3 ; Mortazavijahromi SS1, 4 ; Mohammadimotlagh HR3 ; Mirshafiey A1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
  4. 4. Department of Cellular and Molecular Biology, Kish International Campus, University of Tehran, Kish, Iran

Source: Clinical and Experimental Pharmacology and Physiology Published:2018


Abstract

Angiogenesis is a process through which new capillaries are formed from pre-existing ones, which contributes significantly to the pathogenesis of numerous diseases, such as cancer and chronic inflammatory disorders. The β-D-mannuronic acid (M2000) is a novel non-steroidal anti-inflammatory drug (NSAID) with immunosuppressive effects and is a matrix metalloproteinase (MMP) inhibitor. This research aimed to study the anti-angiogenesis effects of M2000 under in vitro and in vivo models. The cytotoxic and anti-proliferative effects of M2000 were examined using the trypan blue method and the MTT assay, respectively. The 3D collagen-cytodex model and the chick chorioallantoic membrane (CAM) assay were then used to evaluate the anti-angiogenesis property of M2000. Cytotoxicity assay revealed that M2000 (at concentrations of less than 100 μg/mL) had no cytotoxic effect on human umbilical vein endothelial cells (HUVECs). It was also illustrated that M2000 had little or no anti-proliferative effect on HUVECs. In addition, the anti-angiogenesis effects of M2000 were shown to be marginal in the in vitro model and both significant and dose-dependent in the in vivo status. This study showed that M2000 could be considered as an anti-angiogenic molecule which more likely exerts its activity mainly via indirect effects on endothelial cells and its anti-inflammatory effects may partly be attributable to its anti-angiogenic activity. Therefore, it could be recommended as a candidate for prevention and treatment of cancer, chronic inflammatory diseases, and other angiogenesis-related disorders. © 2017 John Wiley & Sons Australia, Ltd
Related Docs
View other Related Docs
1. A Randomized, Controlled, Phase Ii Clinical Trial of Β-D-Mannuronic Acid (M2000) in Pre-Surgical Breast Cancer Patients at Early Stage (T1-T2), Clinical and Experimental Pharmacology and Physiology (2019)
2. The Potent Inhibitory Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Antidsdna Antibodies in Patients With Rheumatoid Arthritis, Current Drug Discovery Technologies (2017)
3. Influence of Β-D-Mannuronic Acid, As a New Member of Non-Steroidal An-Ti-Inflammatory Drugs Family, on the Expression Pattern of Chemokines and Their Receptors in Rheumatoid Arthritis, Current Drug Discovery Technologies (2021)
4. Β-D-Mannuronic Acid (M2000) As a Landmark in Pharmacology, Current Drug Discovery Technologies (2021)
5. International Multicenter Randomized, Placebo-Controlled Phase Iii Clinical Trial of Β-D-Mannuronic Acid in Rheumatoid Arthritis Patients, Inflammopharmacology (2019)
6. A Phase I/Ii Randomized, Controlled, Clinical Trial for Assessment of the Efficacy and Safety of Β-D-Mannuronic Acid in Rheumatoid Arthritis Patients, Inflammopharmacology (2018)
7. Anti-Diabetic Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property on Insulin Production, Blood Glucose, and Inflammatory Markers in the Experimental Diabetes Model, Archives of Physiology and Biochemistry (2019)
8. The Anti-Tumoral Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid on Treg Cells Frequency and Mmp-2, Mmp-9, Ccl22 and Tgfβ1 Gene Expression in Pre-Surgical Breast Cancer Patients, Iranian Journal of Allergy# Asthma and Immunology (2019)
Experts (# of related papers)
View all Related Experts
Mahdi Mahmoudi (9)
Mostafa Hosseini (9)
Other Related Docs
9. Pharmacological Effects of Β-D-Mannuronic Acid (M2000) on Mir-146A, Irak1, Traf6 and Nf-Κb Gene Expression, As Target Molecules in Inflammatory Reactions, Pharmacological Reports (2017)
10. A Controlled, Randomized Phase Ii Clinical Trial for Efficacy and Safety Evaluation of Mannuronic Acid in Secondary Progressive Form of Multiple Sclerosis, International Journal of Neuroscience (2022)
11. Hematological Improvement of Patients With Active Rheumatoid Arthritis by Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property, Iranian Journal of Allergy# Asthma and Immunology (2017)
12. Immunotherapeutic Effects of Β-D Mannuronic Acid on Il-4, Gata3, Il-17 and Rorc Gene Expression in the Pbmc of Patients With Inflammatory Bowel Diseases, Iranian Journal of Allergy# Asthma and Immunology (2018)
13. Clinical Improvement of Diabetes Mellitus Type 1 by Β-D-Mannuronic Acid (M2000) in a Breast Cancer Patient - As a Case Report, Clinical Diabetology (2019)
14. The Potent Suppressive Effect of Β-D-Mannuronic Acid (M2000) on Molecular Expression of the Tlr/Nf-Kb Signaling Pathway in Ankylosing Spondylitis Patients, International Immunopharmacology (2017)
15. Effects of Β-D-Mannuronic Acid, As a Novel Non-Steroidal Anti-Inflammatory Medication Within Immunosuppressive Properties, on Il17, Rorγt, Il4 and Gata3 Gene Expressions in Rheumatoid Arthritis Patients, Drug Design# Development and Therapy (2017)
16. The Effects of Β-D-Mannuronic Acid (M2000), As a Novel Nsaid, on Cox1 and Cox2 Activities and Gene Expression in Ankylosing Spondylitis Patients and the Murine Monocyte/Macrophage, J774 Cell Line, Inflammopharmacology (2018)
17. Introduction of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid With Immunosuppressive Property Based on Cox-1/Cox-2 Activity and Gene Expression, Pharmacological Reports (2017)
18. Modification of Sexual Hormones in Rheumatoid Arthritis Patients by M2000 (Β-D-Mannuronic Acid) As a Novel Nsaid With Immunosuppressive Property, Endocrine# Metabolic and Immune Disorders - Drug Targets (2018)
19. Effect of Β-D-Mannuronic Acid (M2000) on Oxidative Stress Enzymes’ Gene Using Healthy Donor Peripheral Blood Mononuclear Cells for Evaluating the Anti-Aging Property, Current Drug Discovery Technologies (2019)
20. Targeting of Circulating Th17 Cells by Β-D-Mannuronic Acid (M2000) As a Novel Medication in Patients With Rheumatoid Arthritis, Inflammopharmacology (2018)
21. Cardioprotective Effect of Β-D-Mannuronic Acid (M2000) As a Novel Nsaid on Gene Expression of Oxldl Scavenger Receptors in the Experimental Diabetic Model, Immunopharmacology and Immunotoxicology (2018)
22. Immunopharmacological Effect of Β-D-Mannuronic Acid (M2000), As a New Immunosuppressive Drug, on Gene Expression of Mir-155 and Its Target Molecules (Socs1, Ship1) in a Clinical Trial on Rheumatoid Arthritis Patients, Drug Development Research (2020)
23. The Oral Administration Effect of Drug Mannuronic Acid (M2000) on Gene Expression of Matrix and Tissue Inhibitor of Metalloproteinases in Rheumatoid Arthritis Patients, Current Drug Discovery Technologies (2020)
24. The Role of Β-D-Mannuronic Acid, As a New Non-Steroidal Anti-Inflammatory Drug on Expression of Mir-146A, Irak1, Traf6, Nf-Κb and Pro-Inflammatory Cytokines Following a Clinical Trial in Rheumatoid Arthritis Patients, Immunopharmacology and Immunotoxicology (2020)
25. Effects of M2000 (D -Mannuronic Acid) on Learning, Memory Retrieval, and Associated Determinants in a Rat Model of Alzheimer's Disease, American Journal of Alzheimer's Disease and other Dementias (2017)
26. Effects of Mannuronic Acid (M2000) on Gene Expression Profile of Signal Transducer and Activator of Transcription Proteins (Stats) in Rheumatoid Arthritis Patients, Reumatismo (2020)
27. Preclinical Assessment of Β - D -Mannuronic Acid (M2000) As a Non-Steroidal Anti-Inflammatory Drug, Immunopharmacology and Immunotoxicology (2015)
28. M2000 (Β-D-Mannuronic Acid) As a Novel Antagonist for Blocking the Tlr2 and Tlr4 Downstream Signalling Pathway, Scandinavian Journal of Immunology (2017)
29. Preclinical and Pharmacotoxicology Evaluation of Α-L-Guluronic Acid (G2013) As a Non-Steroidal Anti-Inflammatory Drug With Immunomodulatory Property, Immunopharmacology and Immunotoxicology (2017)
30. Β-D-Mannuronic Acid (M2000) and Inflammatory Cytokines in Covid-19; an in Vitro Study, Iranian Journal of Allergy# Asthma and Immunology (2022)
31. The Effects of Mannuronic Acid on Il-1Β, Il-17A, Stat1, and Stat3 Gene Expressions and Tlr2 and Tlr4 Molecules in Multiple Sclerosis, Journal of Clinical Pharmacology (2022)
32. Anti-Tumor Effect of M2000 (Β-D-Mannuronic Acid) on the Expression of Inflammatory Molecules in the Prostate Cancer Cell, Immunopharmacology and Immunotoxicology (2021)
33. The Biology of Β-D-Mannuronic Acid (M2000) on Human Dendritic Cell Based on Microrna-155 and Microrna-221, Current Drug Discovery Technologies (2017)
34. The Inhibitory Role of M2000 (Β-D-Mannuronic Acid) on Expression of Toll-Like Receptor 2 and 4 in Ht29 Cell Line, Recent Patents on Inflammation and Allergy Drug Discovery (2019)
35. Evaluation of Cell Adhesion Molecules (Lfa-1 and L-Selectin) in Ankylosing Spondylitis Patients After Treatment With ß-D-Mannuronic Acid (M2000), Indian Journal of Medical Research (2023)
36. Oral Administration Effects of Β-D-Mannuronic Acid (M2000) on Th17 and Regulatory T Cells in Patients With Ankylosing Spondylitis, Biomedicine and Pharmacotherapy (2018)
37. Immunomodulatory Effects of M2000 (Β-D-Mannuronic Acid) on Tnf-Α, Il-17 and Foxp3 Gene Expression in Patients With Inflammatory Bowel Disease, International Immunopharmacology (2017)
38. Targeting of Crosstalk Between Tumor and Tumor Microenvironment by Β-D Mannuronic Acid (M2000) in Murine Breast Cancer Model, Cancer Medicine (2017)
39. Evaluation of the Efficacy and Safety of Β-D-Mannuronic Acid in Patients With Ankylosing Spondylitis: A 12-Week Randomized, Placebo-Controlled, Phase I/Ii Clinical Trial, International Immunopharmacology (2018)
40. Evaluation of the Effect of Mannuronic Acid As a Novel Nsaid With Immunosuppressive Properties on Expression of Socs1, Socs3, Ship1, and Traf6 Genes and Serum Levels of Il-6 and Tnf-Α in Patients With Multiple Sclerosis, Journal of Clinical Pharmacology (2021)
41. Efficacy of Β-D-Mannuronic Acid [M2000] on the Pro-Apoptotic Process and Inflammatory-Related Molecules Nfҡb, Il-8 and Cd49d Using Healthy Donor Pbmc, Current Drug Discovery Technologies (2020)
42. Evaluating Mannuronic Acid Effect on Gene Expression Profile of Inflammatory Mediators in Rheumatoid Arthritis Patients, Iranian Journal of Allergy# Asthma and Immunology (2022)
43. Anti-Angiogenic Effects of Ethanolic Extract of Artemisia Sieberi Compared to Its Active Substance, Artemisinin, Revista Brasileira de Farmacognosia (2016)
44. The Effect of Β-D-Mannuronic Acid in Animal Model of Epilepsy, Natural Product Communications (2020)
45. An in Vitro Assessment for Evaluating the Efficiency of Β-D-Mannuronic Acid (M2000) in Myelodysplastic Syndrome, Journal of Cellular Physiology (2019)
46. The Evaluation of Safety Property and Apoptotic Efficacy of Α-L-Guluronic Acid (G2013), As a Novel Nsaid, Under in Vitro Examination on L929 and Hepatocellular Carcinoma Cell Lines, Recent Advances in Inflammation and Allergy Drug Discovery (2021)
47. The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients, Recent Patents on Inflammation and Allergy Drug Discovery (2020)
48. Anti‐Inflammatory and Anti‐Tumor Effects of Α-L-Guluronic Acid (G2013) on Cancer-Related Inflammation in a Murine Breast Cancer Model, Biomedicine and Pharmacotherapy (2018)
49. The Anti-Migraine Effects of M2000 (Β-D-Mannuronic Acid) on a Patient With Rheumatoid Arthritis: Case Report, Current Clinical Pharmacology (2017)
50. Evaluation of the Effect of Α-L-Guluronic Acid (G2013) on Cox-1, Cox-2 Activity and Gene Expression for Introducing This Drug As a Novel Nsaid With Immunomodulatory Property, Recent Patents on Inflammation and Allergy Drug Discovery (2018)